Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
HER2-Positive Early Stage Breast Cancer
Interventions
DRUG

Paclitaxel

DRUG

Trastuzumab

The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.

DRUG

Lapatinib

DRUG

Pegfilgrastim

Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

11725

Memorial Sloan-Kettering Cancer Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

Unknown

Memorial Sloan Kettering Rockville Centre, Rockville Centre

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER